The proposed research will compare the effects of TBI prior to CAR T cell infusion to the current standard of care using lymphodepletion.
Patients must have a confirmed diagnosis of Acute Lymphoblastic Lymphoma and are planned to undergo CAT T cell therapy. The patient should not be planned to receive craniospinal irradiation prior to CAR T therapy; the latter group will be excluded from this study. Prior Radiation would not exclude patients from getting 2 Gy TBI, including prior TBI, in the event of a prior stem cell transplant.
Age ≥18 years.
ECOG performance status ≤2 (Karnofsky ≥60%,).
Patients must have adequate organ and marrow function as defined below: absolute neutrophil count ≥1,000/mcL Platelets ≥100,000/mcL total bilirubin ≤ institutional upper limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN creatinine ≤ institutional ULN
Patients who are receiving any other investigational agents.
Patients who need craniospinal irradiation for CNS leukemia prior to CAR T cell therapy.
Patients with uncontrolled intercurrent illness (Indicate clearly what type or extent)
Patients with psychiatric illness/social situations that would limit compliance with study requirements.
Single group
CAR T cell therapy
DrugCAR T cell therapy will be administered as per the institutional guidelines and as per our standard of care
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
